Lead Dis­cov­ery Cen­ter (LDC)

We are look­ing for Sci­ent­ist­s/­­Post-doc to join our team (full-time position).

The Uni­S­ens tech­no­logy is a single-assay plat­form designed from the ground-up to sup­port the next gen­er­a­tion of drug dis­cov­ery and will enable detec­tion and func­tional clas­si­fic­a­tion of drug can­did­ates with super­ior con­fid­ence com­pared to today’s approaches.

Our pro­jects at a glance

With its devel­op­ment pro­ject GO-Immun for the treat­ment of autoim­mune dis­eases, ISAR Bioscience has once again been able to con­vince a renowned fund­ing agency.

The Bav­arian research com­pany ISAR Bioscience is well on the way to a new Alzheimer’s therapy.

ISAR Bioscience has been gran­ted a man­u­fac­tur­ing author­isa­tion in accord­ance with the Ger­man Medi­cines Act (§13 AMG) and a GMP (Good Man­u­fac­tur­ing Prac­tice) cer­ti­fic­a­tion for its facil­ity in Planegg near Munich.

In the cooper­a­tion pro­ject with the Uni­ver­sity of Munich, cell cul­ture mod­els will be cre­ated for the devel­op­ment of novel drug therapies.

The European Innov­a­tion Coun­cil (EIC) has announced the selec­tion of pro­pos­als from the 2023 EIC Pathfinder Open call, which funds ideas for new break­through technologies.

Sci­ent­ists of the BASE-Lipid con­sor­tium met for two days at Evonik’s Hanau site to fur­ther coordin­ate their joint research.

We developed a com­pet­it­ive chemi­lu­min­es­cence immun­oas­say that enables the detec­tion of neut­ral­iz­ing SARS-CoV-2 anti­bod­ies within 7 min.